Danaher Reports Third Quarter 2024 Results
Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the quarter ended September 27, 2024. All results in this release reflect only continuing operations unless otherwise noted.
10.22.2024
Danaher Schedules Third Quarter 2024 Earnings Conference Call
Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the third quarter 2024 on Tuesday, October 22, 2024 beginning at 8:00 a.m. ET and lasting...
09.19.2024
Danaher Announces Quarterly Dividend
Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.27 per share of its common stock, payable on October 25, 2024 to...
09.10.2024
Danaher Confirms Third Quarter and Full Year 2024 Guidance
Danaher Corporation (NYSE: DHR) (the "Company") confirmed its previously issued guidance for the third quarter and full year 2024 ahead of a previously scheduled analyst event. The Company...
09.04.2024
Danaher to Webcast Diagnostics Investor & Analyst Meeting in Washington, D.C.
Danaher Corporation (NYSE: DHR) will host a live video webcast of its Diagnostics Investor and Analyst Meeting in Washington, D.C. on September 5, 2024 beginning at approximately 10:00 a.m. ET....
08.26.2024
Danaher Reports Second Quarter 2024 Results
Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the quarter ended June 28, 2024. All results in this release reflect only continuing operations unless otherwise noted....
07.23.2024
Danaher Announces Two New Centers of Innovation in Diagnostics to Transform Precision Medicine Development
DH Diagnostics LLC Centers aim to accelerate drug development by speeding and streamlining development and commercialization of companion diagnostics. Clinical Laboratory Improvement Amendments...
07.17.2024
Danaher Releases 2024 Sustainability Report
Danaher Corporation (NYSE: DHR) ("Danaher" or the "Company"), the global life sciences and diagnostics innovator, today published its 2024 Sustainability Report which conveys the depth and scope...
07.16.2024
Danaher Launches Beacon Research Collaboration with Stanford University Aiming to Build Next Generation of Smart Microscopes for Cancer Drug Screening
Predictive tools will seek to reduce leading cause of failure rates in clinical trials of oncology drugs. Integrated AI and microscopy expected to lead to better understanding of tumor structures...
07.11.2024
Danaher Schedules Second Quarter 2024 Earnings Conference Call
Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the second quarter 2024 on Tuesday, July 23, 2024 beginning at 8:00 a.m. ET and lasting...
06.24.2024
Danaher appoints Julie Sawyer Montgomery to Executive Vice President for Diagnostics
Danaher Corporation (NYSE: DHR) ("Danaher" or the "Company"), a leading global life sciences and diagnostics innovator, today announced that Julie Sawyer Montgomery will succeed Joakim Weidemanis...
06.19.2024
Danaher Appoints Martin Stumpe to New Role of Chief Data & Artificial Intelligence Officer
Move reflects increasing investment in AI as driving force for innovation and productivity. Company will host Innovation Summit in December focused on AI in R&D. WASHINGTON, June 5, 2024...
06.05.2024
Danaher Launches Collaboration with Johns Hopkins University Aiming to Improve Neurological Diagnosis
The Danaher Beacon for Brain Injury Diagnostics seeks to identify mild Traumatic Brain Injury (TBI) earlier and more precisely. Scientists will evaluate new blood-based biomarkers using highly...
05.09.2024
Danaher to Present at Bank of America Securities Healthcare Conference
Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the at the Bank of America Securities Health Care Conference in Las...
05.07.2024
Danaher Announces Quarterly Dividend
Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.27 per share of its common stock, payable on July 26, 2024 to...
05.07.2024
Danaher Reports First Quarter 2024 Results
Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the quarter ended March 29, 2024. All results in this release reflect only continuing operations unless otherwise noted....
04.23.2024
Danaher Schedules First Quarter 2024 Earnings Conference Call
Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the first quarter 2024 on Tuesday, April 23, 2024 beginning at 8:00 a.m. ET and lasting...
03.21.2024
Danaher to Present at TD Cowen Health Care Conference
Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the TD Cowen Healthcare Conference in Boston, Massachusetts on Tuesday,...
02.27.2024
Danaher Commits to Set Science-Based, Net-Zero Greenhouse Gas Emission Reduction Targets
Danaher Corporation (NYSE: DHR) (Danaher) announced today it has committed to set science-based greenhouse gas (GHG) emission reduction targets in line with the Science Based Targets initiative...
02.22.2024
Danaher Announces Quarterly Dividend
Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.27 per share of its common stock, payable on April 26, 2024 to...
02.21.2024
Danaher Launches Collaboration with Cincinnati Children's Hospital Medical Center Aiming to Improve Patient Safety in Early Drug Development
Danaher Beacon for Preclinical Drug Safety seeks to address major cause of failure in clinical trials Program will leverage automated liver organoid technology for drug toxicity screening Aims to...
02.05.2024
Danaher Reports Fourth Quarter and Full Year 2023 Results
Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the fourth quarter and full year 2023. All results in this release reflect only continuing operations unless otherwise...
01.30.2024
Danaher, Jennifer Doudna, and Innovative Genomics Institute Launch Danaher-IGI Beacon for CRISPR Cures with Aim to Address Hundreds of Diseases Using Gene-editing Platform Solution
New collaborative research center based at University of California, Berkeley, plans to develop platform approaches that can be easily modified to develop gene-editing medicines for hundreds of...
01.09.2024
Danaher CEO to Comment on Financial Performance
Danaher Corporation (NYSE: DHR) (the "Company") announced that its President and Chief Executive Officer, Rainer M. Blair, will comment tomorrow on the Company's fourth quarter 2023 performance in...
01.08.2024
Danaher to Present at J.P. Morgan Healthcare Conference
Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the J.P. Morgan Healthcare Conference in San Francisco, California on...
01.02.2024
Danaher Schedules Fourth Quarter 2023 Earnings Conference Call
Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the fourth quarter 2023 on Tuesday, January 30, 2024 beginning at 8:00 a.m. ET and lasting...
12.21.2023
Danaher Completes Acquisition of Abcam
Danaher Corporation (NYSE:DHR) ("Danaher") announced today it has completed its acquisition of Abcam plc (NASDAQ:ABCM) ("Abcam"). The acquisition of Abcam for $24.00 per share in cash was...
12.06.2023
Danaher Announces Quarterly Dividend
Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.24 per share of its common stock, payable on January 26, 2024 to...
12.05.2023
Danaher to Present at Evercore ISI HealthCONx Conference
Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the Evercore ISI HealthCONx Conference in Miami, Florida on Wednesday,...
11.21.2023
Danaher appoints Christopher Riley to Executive Vice President for Biotechnology
Danaher Corporation (NYSE: DHR) ("Danaher" or the "Company"), a leading global life sciences and diagnostics innovator, today announced that Christopher Riley has been appointed by its Board of...
10.31.2023
Danaher Reports Third Quarter 2023 Results
Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the third quarter ended September 29, 2023. Net earnings refer to net earnings attributable to common shareholders....
10.24.2023
Danaher Corporation Completes Separation of Veralto Corporation
Danaher Corporation (NYSE: DHR) announced today that it has completed the separation of its Environmental & Applied Solutions segment, through the spin-off of Veralto Corporation. Veralto will...
09.30.2023
Danaher Schedules Third Quarter 2023 Earnings Conference Call
Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the third quarter 2023 on Tuesday, October 24, 2023 beginning at 8:00 a.m. ET and lasting...
09.26.2023
Danaher to Provide Cepheid's Tuberculosis Test to the Global Fund at Cost
New agreement aims to provide greater access to millions more high-quality tuberculosis (TB) tests for people living in the least developed countries where the need is most urgent. Enables the...
09.19.2023
Danaher Announces Quarterly Dividend
Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.27 per share of its common stock, payable on October 27, 2023 to...
09.12.2023
Danaher and Veralto to Webcast Investor and Analyst Meeting
Danaher Corporation (NYSE: DHR) will host a live video webcast of Veralto's Investor and Analyst Meeting on September 6, 2023 beginning at approximately 12:00 p.m. CT. The event, which will...
08.31.2023
Danaher to Acquire Abcam
Danaher Corporation (NYSE: DHR) ("Danaher" or the "Company"), a global science and technology innovator, announced today that it has entered into a definitive agreement to acquire Abcam plc...
08.28.2023
Danaher Declares pro Rata Dividend of Veralto Common Stock and Announces Expected "When-issued" Trading of Veralto Common Stock
Danaher Corporation (NYSE: DHR) today announced that it expects to complete the previously announced separation of Veralto Corporation on September 30, 2023, the first day of Danaher's fiscal...
08.25.2023
Danaher Releases 2023 Sustainability Report
Danaher Corporation (NYSE: DHR) ("Danaher" or the "Company"), the global science and technology innovator, today published its 2023 Sustainability Report which conveys the depth and scope of...
08.16.2023
Danaher Reports Second Quarter 2023 Results
Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the second quarter 2023. Net earnings refer to net earnings attributable to common shareholders. For the quarter ended...
07.25.2023
Danaher Schedules Second Quarter 2023 Earnings Conference Call
Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the second quarter 2023 on Tuesday, July 25, 2023 beginning at 8:00 a.m. ET and lasting...
06.20.2023
Danaher Announces Quarterly Dividend
Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.27 per share of its common stock, payable on July 28, 2023 to...
05.09.2023
Danaher to Present at Bank of America Securities Health Care Conference
Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the Bank of America Securities Health Care Conference in Las Vegas,...
05.03.2023
Danaher Reports First Quarter 2023 Results
Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the first quarter 2023. Net earnings refer to net earnings attributable to common shareholders. For the quarter ended...
04.25.2023
Danaher Announces Conversion Date for Series B Mandatory Convertible Preferred Stock
Danaher Corporation (NYSE: DHR) announced today that its 5.00% Series B Mandatory Convertible Preferred Stock (the "Preferred Stock"), will automatically convert into shares of the Company's...
04.10.2023
Danaher Schedules First Quarter 2023 Earnings Conference Call
Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the first quarter 2023 on Tuesday, April 25, 2023 beginning at 8:00 a.m. ET and lasting...
03.27.2023
Danaher Partners with the University of Pennsylvania's Center for Cellular Immunotherapies to Address Manufacturing Challenges Impacting the Uptake of Cell Therapies
Danaher Corporation (NYSE: DHR), a global science and technology innovator, today announced a strategic partnership with the University of Pennsylvania (Penn) focusing on cell therapy innovation....
03.07.2023
Danaher Announces Quarterly Dividends
Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.27 per share of its common stock, payable on April 28, 2023 to...
02.22.2023
Danaher Announces New Environmental and Applied Solutions Company to Be Named Veralto
Danaher Corporation (NYSE: DHR) ("Danaher") today announced that Veralto Corporation ("Veralto" or the "Company") will be the name of the separate public company Danaher intends to create in the...
02.08.2023
Danaher Reports Fourth Quarter and Full Year 2022 Results
Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the fourth quarter and full year 2022. All results in this release reflect only continuing operations unless otherwise...
01.24.2023